• 

 

 

(JNU Prof. Park Se-Pill's team, non-clinical trials in Nature's international journal ‘Scientific Reports’)

On Dec. 27, JNU announced that Prof. Park Se-pill's team from the Department of Biomedical Information published a paper on the improvement of urticaria disease through the administration of allogeneic embryonic stem cells (MMSC) in Nature Publication 'Scientific Reports', the prestigious international journal.

This study was organized by Mirae Cell Bio Co., Ltd. and was conducted in collaboration with Prof. Kim Hyuk-soon of the Department of Biomedical Sciences at Dong-A University and Dr. Noh Gun-woong of Halla Hospital.

It proved that it is effective in non-clinical models of urticaria disease, an incurable chronic disease, by expanding the application of Multifunctional Mesenchymal Stem Cell (MMSC), which has been proven to alleviate diseases in existing interstitial cystitis.

Chronic urticaria disease is an intractable disease that significantly lowers the quality of life, and so far, most of them can only prescribe antihistamines that show temporary relief effects, so the development of new treatments is urgent.

In the disease model, the MMSC treatment was 1.5 times better than the administration of antihistamines and 2.6 times better than the administration of bone marrow-derived mesenchymal stem cells.

The mechanism of action was also identified by inhibiting the activity of mast cells that secrete inflammatory T cells and histamine through the action of the anti-inflammatory cytokine TGF-beta among MMSC-derived secretion factors.

JNU prof. Park Se-pill said, "This study is a typical case of successful industry-academia cooperation supported by Mirae Cell Bio Co., Ltd. It is expected that this study will lead to research on the development of cell therapy for the world's first 'human dementia-induced cloned Jeju black pig (JNUPIG, 2017)' developed by JNU to further expand the application of MMSC."